FOLSOM, Calif. — CGT Global, a biotechnology firm specializing in cell and gene therapies, has appointed Dr. Andrew Robert Branagan to its Board of Advisors, aiming to bolster its scientific and clinical leadership in the field of hematologic malignancies and cellular therapies.
Dr. Branagan currently serves as a Clinical Investigator and Medical Director at Massachusetts General Hospital (MGH) and is an Assistant Professor of Medicine at Harvard Medical School. He also sits on the MGH Cellular Therapy Steering Committee. His new advisory role will complement his existing position as CGT Global’s Medical Director, which he has held since 2018.
“We are thrilled to welcome Dr. Andrew Branagan to our Board of Advisors,” said Cate Spears, CEO and Founder of CGT Global. “His profound understanding of the human immune system, particularly in the context of plasma cell disorders like multiple myeloma and Waldenstrom’s macroglobulinemia, combined with his direct experience in clinical trials of advanced therapies, will be invaluable as we advance our cell and gene therapy pipeline.”
Dr. Branagan earned his PhD in Investigative Medicine from Yale University, where he focused on vaccine strategies to improve immune responses in patients with blood cancers. He is board-certified in Internal Medicine, Medical Oncology, and Hematology, and has contributed to multiple scientific advisory boards in the oncology sector.
“The potential of these innovative modalities to transform patient care is immense, and I look forward to contributing my expertise in clinical development, immunology, and hematologic oncology to help guide CGT Global in its mission to bring life-changing therapies to patients in need,” said Dr. Branagan.
He is also active in medical education and global health initiatives and holds memberships in several professional bodies, including the American Society of Hematology, American Society of Clinical Oncology, and the International Myeloma Working Group.
